Global Partners
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude ...
Latest News
18 hours ago · globenewswire.com
Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026Omada's AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16. In Omada's GLP-1 Care Track, 71% of members stayed on their medication for a full year, and those who did lost 18.4% of body weight, comparable to clinical trials.
1 day ago · nypost.com
CVS says GLP-1s save money when priced below $350 per monthThe analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking the drugs.
4 days ago · zacks.com
Global Partners (GLP) Moves to Strong Buy: Rationale Behind the UpgradeGlobal Partners (GLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 days ago · zacks.com
Best Value Stocks to Buy for November 12thPANL, GLP, and LRN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 12, 2026.
5 days ago · zacks.com
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
5 days ago · fxempire.com
Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New HighsMcKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
6 days ago · seekingalpha.com
Hims & Hers Health: Don't Nitpick Quarterly ResultsHims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. HIMS strategically reduced marketing spend to prepare for the Eli Lilly GLP-1 partnership, international brand consolidation, and upcoming peptide product launch. Gross margins slipped to 57% due to Eucalyptus integration, though margins are likely to remain lower due to branded GLP-1 deals.
6 days ago · fool.com
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?Eli Lilly has been generating incredible growth in recent quarters due to its top GLP-1 drugs. Novo Nordisk has struggled due to sluggish numbers, but a higher-dose version of Wegovy could change that.
6 days ago · globenewswire.com
Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue RestorationHighlights Conexeu has launched a human collagen initiative at its Vancouver research and development facility, for its aesthetics program, focused on potential tissue-restoration applications associated with aging and significant weight loss, including GLP-1-associated weight loss. The patented CXU™ formula has already been evaluated with human collagen from various sources in the 12-month P.R.O.O.F.
6 days ago · globenewswire.com
Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026SAN CARLOS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on diabetes and obesity, today announced that it will present Phase 1 clinical results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, at ObesityWeek® 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GLP